+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Hurthle Cell Carcinoma Treatment Market by Treatment, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5674555
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hurthle Cell Carcinoma Treatment Market grew from USD 6.44 billion in 2023 to USD 6.82 billion in 2024. It is expected to continue growing at a CAGR of 6.41%, reaching USD 9.96 billion by 2030.

Hurthle Cell Carcinoma (HCC) treatment is within the broader realm of thyroid cancer therapy, underscoring its complex pathology and unique cellular characteristics that necessitate specialized treatment modalities. The primary necessity for developing effective HCC treatments stems from its rarity and distinctive aggressive behavior compared to other thyroid malignancies, thus demanding innovative therapeutic approaches. Applications range from surgical interventions and radioactive iodine treatments to novel targeted therapies like tyrosine kinase inhibitors when traditional methods fail. The end-use scope includes healthcare providers, hospitals, and oncology clinics that offer HCC treatments, alongside emerging biopharmaceutical companies exploring cutting-edge therapies.

Market insights point to an increasing incidence rate coupled with a better understanding of cancer biology, significantly driving the market. Key growth influencers include advancements in precision medicine, a heightened emphasis on early diagnosis, and the integration of artificial intelligence in predictive oncology for personalized treatment plans. Potential opportunities lie in the development of gene therapies and personalized medicine, leveraging advancements in genomics that facilitate targeted treatment approaches specific to HCC's genetic mutations. Companies aiming to capitalize on this should invest in R&D for treatments with higher efficacy and fewer side effects.

However, challenges abound due to the cancer's low prevalence, limiting the scope for large-scale clinical trials and deterring substantial investment into R&D specific to HCC. Regulatory hurdles, coupled with high costs of cutting-edge treatments and a lack of awareness, further impede market growth. Areas ripe for innovation include improving diagnostic accuracy through artificial intelligence and machine learning, as well as creating more effective targeted therapies that minimize off-target effects. Maintaining a robust pipeline of research focused on molecular mechanisms and immunotherapies could propel business growth. The market, though niche, exhibits the dynamic nature of oncology therapeutics, driven by technological advancements and the growing need for precision medicine solutions tailored to rare cancer types such as HCC.

Understanding Market Dynamics in the Hurthle Cell Carcinoma Treatment Market

The Hurthle Cell Carcinoma Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing thyroid related diseases
    • Rising healthcare awareness about necessity of treatment
    • Increase in government initiatives
  • Market Restraints
    • Dearth of skilled professionals for the treatment of HCC
  • Market Opportunities
    • Technological developments in HCC treatment
    • Growing research and development activities of HCC treatment
  • Market Challenges
    • Adverse effects of the chemotherapy and lack of patient awareness

Exploring Porter’s Five Forces for the Hurthle Cell Carcinoma Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Hurthle Cell Carcinoma Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Hurthle Cell Carcinoma Treatment Market

External macro-environmental factors deeply influence the performance of the Hurthle Cell Carcinoma Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Hurthle Cell Carcinoma Treatment Market

The Hurthle Cell Carcinoma Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Hurthle Cell Carcinoma Treatment Market

The Hurthle Cell Carcinoma Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Hurthle Cell Carcinoma Treatment Market

The Hurthle Cell Carcinoma Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hurthle Cell Carcinoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company, Eurofins Scientific SE, Illumina Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer, Inc., Provell Pharmaceuticals, LLC, Qiagen N.V., Sanofi S.A., Sorrento Therapeutics, Inc., Teikoku Seiyaku Co. Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Hurthle Cell Carcinoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Treatment
    • General Surgery
    • Radioactive Iodine
    • Robotic Surgery
    • Total Thyroidectomy
  • End User
    • Ambulatory Surgical Center
    • Clinic
    • Hospital
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing thyroid related diseases
5.1.1.2. Rising healthcare awareness about necessity of treatment
5.1.1.3. Increase in government initiatives
5.1.2. Restraints
5.1.2.1. Dearth of skilled professionals for the treatment of HCC
5.1.3. Opportunities
5.1.3.1. Technological developments in HCC treatment
5.1.3.2. Growing research and development activities of HCC treatment
5.1.4. Challenges
5.1.4.1. Adverse effects of the chemotherapy and lack of patient awareness
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Hurthle Cell Carcinoma Treatment Market, by Treatment
6.1. Introduction
6.2. General Surgery
6.3. Radioactive Iodine
6.4. Robotic Surgery
6.5. Total Thyroidectomy
7. Hurthle Cell Carcinoma Treatment Market, by End User
7.1. Introduction
7.2. Ambulatory Surgical Center
7.3. Clinic
7.4. Hospital
8. Americas Hurthle Cell Carcinoma Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Hurthle Cell Carcinoma Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Hurthle Cell Carcinoma Treatment Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. HURTHLE CELL CARCINOMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 9. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. HURTHLE CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. HURTHLE CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. HURTHLE CELL CARCINOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. HURTHLE CELL CARCINOMA TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROBOTIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TOTAL THYROIDECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 24. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 26. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 30. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 31. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. AUSTRALIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. AUSTRALIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. CHINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 36. CHINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. INDIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. INDIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. INDONESIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. INDONESIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. JAPAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. JAPAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. MALAYSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. MALAYSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. PHILIPPINES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. PHILIPPINES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. SINGAPORE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. SINGAPORE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. SOUTH KOREA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. SOUTH KOREA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. TAIWAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. TAIWAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. THAILAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. THAILAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. VIETNAM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. VIETNAM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. DENMARK HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. DENMARK HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. EGYPT HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. EGYPT HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. FINLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. FINLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. ISRAEL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. ISRAEL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. NETHERLANDS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. NETHERLANDS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. NIGERIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. NIGERIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. NORWAY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. NORWAY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. POLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. POLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. QATAR HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. QATAR HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. SWEDEN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. SWEDEN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. SWITZERLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. SWITZERLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. TURKEY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. TURKEY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. HURTHLE CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 103. HURTHLE CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Hurthle Cell Carcinoma Treatment Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • Eurofins Scientific SE
  • Illumina Inc.
  • Merck KGaA
  • Novartis AG
  • PerkinElmer, Inc.
  • Pfizer, Inc.
  • Provell Pharmaceuticals, LLC
  • Qiagen N.V.
  • Sanofi S.A.
  • Sorrento Therapeutics, Inc.
  • Teikoku Seiyaku Co. Ltd.
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information